Increased prandial GLP-1-induced insulin secretion after gastric bypass (GB), especially in those with late-complication of hypoglycemia, is well characterized. We previously reported that meal ingestion increases insulin and GLP-1 secretion during a sub-basal glycemic clamp in individuals after GB. Here, we investigated whether altered meal-stimulated β-cell output in this setting is due to the enhanced glucose-independent actions of GLP-1 using a potent GLP-1 receptor (GLP-1R) antagonist, exendin-(9-39) (Ex-9). Nine subjects with history of GB, 6 with prior sleeve gastrectomy (SG), and 4 non-operated healthy subjects were studied twice with and without Ex-9 infusion during a 5-hr hyperinsulinemic (120mU/m2/min) hypoglycemic (55mg/dl) clamp. The GB, SG, and CN groups were matched for BMI, FFM, A1c, and age; and the GB and SG for weight loss and time postsurgery; none had diabetes. Islet and gut hormones were measured before and after a liquid meal (280kcal, 20% glucose) at 2 hr of clamp studies. Fasting levels of glucose, islet and GI hormones were similar between 2 studies and among 3 groups. Insulin sensitivity (M/I) didn’t differ among the groups but insulin clearance was larger in surgical patients (P=0.08). Blocking GLP-1R did not affect β-cell secretory response before or after meal ingestion whereas α-cell responses to hypoglycemia alone or to meal ingestion were increased during Ex-9 infusion (pre-meal: 18, 9, 47%, and post-meal: 42, 14, 13% in GB, SG, and CN, respectively, P<0.05). Prandial GIP was similar among 3 groups and not affected by Ex-9. GLP-1 response was larger in GB compared to SG and CN, and was further increased by Ex-9 (P<0.01). Our findings indicate that in nondiabetic subjects with prior history of GB and SG, endogenous GLP-1 contribution to prandial β-cell secretion is glucose-dependent. Glucagonostatic effect of endogenous GLP-1, on the other hand, is preserved during hypoglycemic condition after these surgeries.

Disclosure

H. Honka: None. A.M. Al Zubaidi: None. A. Gastaldelli: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Gilead Sciences, Inc., Inventiva Pharma, Novo Nordisk Inc. R.A. DeFronzo: None. M. Salehi: None.

Funding

Finnish Cultural Foundation (00180071); National Institutes of Health (DK105379)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.